Nomura Holdings Inc Neurocrine Biosciences Inc Call Options Transaction History

Nomura Holdings Inc

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$114.58 - $153.15 $607,274 - $811,695	-5,300 Reduced 31.55%	11,500 $1.32 Million
Q2 2024 Aug 14, 2024	BUY	$130.86 - $143.19 $2.2 Million - $2.41 Million	16,800 New	16,800 $2.31 Million
Q3 2022 Nov 15, 2022	SELL	$92.03 - $107.81 $4.11 Million - $4.82 Million	-44,700 Reduced 49.89%	44,900 $4.77 Million
Q2 2022 Aug 15, 2022	BUY	$75.79 - $100.07 $1.96 Million - $2.58 Million	25,800 Added 40.44%	89,600 $8.89 Million
Q1 2022 May 18, 2022	SELL	$72.45 - $94.81 $1.17 Million - $1.54 Million	-16,200 Reduced 20.25%	63,800 $6.1 Million
Q2 2020 Aug 14, 2020	BUY	$85.09 - $130.36 $6.81 Million - $10.4 Million	80,000 New	80,000 $9.77 Million
Q1 2020 May 14, 2020	SELL	$75.11 - $113.76 $2.25 Million - $3.41 Million	-30,000 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$86.8 - $118.57 $868,000 - $1.19 Million	10,000 Added 50.0%	30,000 $3.22 Million
Q2 2019 Aug 14, 2019	SELL	$72.24 - $91.27 $722,400 - $912,700	-10,000 Reduced 33.33%	20,000 $1.7 Million
Q1 2019 May 14, 2019	BUY	$69.31 - $91.53 $2.08 Million - $2.75 Million	30,000 New	30,000 $0

625

94.2M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Nomura Holdings Inc, based on Form 13F filings with the SEC.

Stay updated on Nomura Holdings Inc with notifications on news.